Cytotoxic Properties of Novel Pyrazole Derivatives (BK-31 & BK-33) on Human Breast Cancer (MDA-MB-231) and Mouse Embryonic Fibroblast (NIH/3T3) Cells

Damiron, Siti Nadia (2020) Cytotoxic Properties of Novel Pyrazole Derivatives (BK-31 & BK-33) on Human Breast Cancer (MDA-MB-231) and Mouse Embryonic Fibroblast (NIH/3T3) Cells. [Project Paper] (Submitted)

Text FPSK2 2020 8.pdf Download (1MB)

Abstract

Breast cancer is a life-threatening illness and the number of deaths associated with breast cancer is increasingly alarming. More than 90% of patients with breast cancer suffer from chronic tumour metastases, as the cancer cells’ ability to migrate to the surrounding tissues has contributed to poor prognosis in cancer diagnosis. Given the presence of many anticancer drugs, there is still no currently available agents capable of eliminating cancer cells without damaging the normal tissues. Hence, the development of newer chemotherapeutic scaffolds that act selectively on the target site without side effects has become a primary goal of researchers. In order to produce anti-metastatic targeted therapy, it is significant to identify a compound that can prevent the migration of the cancer cells. Novel pyrazole molecule, a five-member heterocyclic chain is thought to have anti-cancer properties. However, to our knowledge, studies of the newly discovered derivatives of this pyrazole molecule on the migration of breast cancer cells has yet to be explored. Prior to studying its anti-migration effects, the cytotoxic properties of the compound have to be investigated. This study generally aims to determine the cytotoxic properties of novel pyrazole derivatives towards both breast cancer and normal fibroblast cells. Methodology: Human breast cancer cells (MDA-MB-231) and mouse embryonic fibroblast cells (NIH/3T3) are used as an in vitro model. MDA-MB-231 and NIH/3T3 cells are cultured in DMEM prior to MTT assay which is employed to determine the cytotoxic properties (IC50) of the novel pyrazole derivatives towards both cell lines, at different incubation time points (24, 48 and 72 hours). Results: In MTT assay, the IC50 values for MDA-MB-231 cells treated with BK-33 are 103 µM and 64 µM after 48- and 72-hour of treatment respectively. These results showed that the IC50 is significantly decreased in a dose- and time-dependent manner. In comparison with NIH/3T3 cells treated with BK-33, there is no cytotoxicity effects exerted by the compound. Another compound which is BK-31 shows no IC50 values recorded across three different incubation periods in both cell lines. Conclusion: With more validation studies done, novel pyrazole derivatives specifically BK-33 may be a good candidate for chemotherapeutic against breast cancer as it exhibits cytotoxic effects in only breast cancer cells and not in the normal fibroblast cells.

Item Type:	Project Paper
Faculty:	Faculty of Medicine and Health Science
Depositing User:	Ms. Nor Safa'aton Saidin
Date Deposited:	23 Aug 2023 00:11
Last Modified:	23 Aug 2023 00:11
URI:	http://psaspb.upm.edu.my/id/eprint/1290

Actions (login required)

View Item